PCSK9 and type 2 diabetes mellitus: In addition, the PCSK9 inhibitor alirocumab significantly reduces cholesterol and LDL levels regardless of sex among individuals with type 2 diabetes and atherosclerotic cardiovascular disease presenting high non-HDL-C/LDL-C levels [28], and alirocumab is an effective therapeutic option for patients with type 2 diabetes and mixed dyslipidemia [29].